Books > Academic & Education > Varsity Textbooks > Nursing
|
Not currently available
Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners (Hardcover, 1st ed. 2019)
Loot Price: R845
Discovery Miles 8 450
You Save: R657
(44%)
|
|
Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners (Hardcover, 1st ed. 2019)
Supplier out of stock. If you add this item to your wish list we will let you know when it becomes available.
|
This book aims to educate nurses and advanced practice providers
(APP's) about known mutations, availability of targeted therapy and
the management of patients with non-small cell lung cancer (NSCLC).
It will educate nurses and practitioners about the scope of therapy
to assure safe and effective lung cancer treatment. In this era of
personalized medicine, nurses and APP's are responsible for guiding
patients from diagnosis through treatment. This starts with the
identification of patients that can benefit from these therapies,
the key role of biopsy acquisition (ie. what to test, when and how
often) and treatment selection based on the mutation identified.
Readers will learn about the mechanisms of action, administration,
potential adverse side effects and unique management strategies for
these targeted agents. Lung cancer continues to be the leading
cause of cancer death in the United States and worldwide. Recent
advances in the identification of specific oncogenic mutations that
drive cancer development, growth and metastasis have led to major
paradigm shifts in lung cancer treatment. Sophisticated methods are
required to identify specific mutations at the time of diagnosis.
This book explains how molecularly targeted therapies have been
developed that target these drivers. To date, several tyrosine
kinase inhibitors have been approved to target the epidermal growth
factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently,
immune checkpoint inhibitors have been approved with some
indication that efficacy may be enhanced for patients who
overexpress PD-L1. While some driver mutations have been
identified, there is ongoing investigation into additional
mutations. In the case of driver mutations, lung cancers will
develop resistance to therapy. This book provides nurses and APP's
with the mechanisms of resistance that have been identified such as
T790 mutation and many others in the EGFR mutation, and shows how
the next level of drug development is focused on identifying
mechanisms of resistance and development of new agents that
overcome these mutations. With this book in hand, nurses and
practitioners will be able to navigate patients through this ever
expanding field of lung cancer treatment.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.